Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1796–1805. doi: 10.1161/ATVBAHA.117.310672

Figure 6. Macrophage differentiation in human PBMCs after AngII priming and stimulation.

Figure 6

Human PBMCs were isolated and primed with AngII or AngII/IL-10 for 24 hours before cells were activated with LPS (24h) to further evaluate macrophage activation (n=9/18/19)

A) Relative expression of TNF-α (TNF) over GAPDH in unprimed, AngII-primed, and AngII/IL-10 primed PBMCs; ** = p≤0.01 vs. AngII.

B) Relative expression of IL-10 in unprimed, AngII, and AngII/IL-10 PBMCs; * = p≤0.05 vs. AngII.

C) Ratio (relative expression) of TNF over IL-10; ** = p≤0.01 vs. AngII, ## = p≤0.01 vs. unprimed

D) Relative expression of MRC1 in unprimed, AngII, and AngII/IL-10 PBMCs; ** = p≤0.01 vs. AngII.

E) Relative expression of CD163 in unprimed, AngII, and AngII/IL-10 PBMCs; ** = p≤0.01 vs. AngII.

F) Relative expression of IL-6 in unprimed, AngII, and AngII/IL-10 PBMCs; ** = p≤0.01 vs. AngII.

HHS Vulnerability Disclosure